For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.
Scope of the Report:
This report focuses on the Pulmonary Hypertension Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Pulmonary Hypertension Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co., Inc.
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd.
- Vectura Group plc
- Pfizer Inc.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists
- Phosphodiesterase-5 Inhibitors
- Soluble Guanylate Cyclase Stimulators
Market Segment by Applications, can be divided into
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
There are 15 Chapters to deeply display the global Pulmonary Hypertension Drug market.
Chapter 1, to describe Pulmonary Hypertension Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pulmonary Hypertension Drug, with sales, revenue, and price of Pulmonary Hypertension Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pulmonary Hypertension Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pulmonary Hypertension Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pulmonary Hypertension Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source